Identification of Biomarkers in the Legal Medical Skin Wounds

Identification of Protein Markers of Vitality in Skin Wounds by Forensic Multiplex Analysis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02898636

Enrollment

Registered

2016-09-13

Start date

2016-09-01

Completion date

2020-03-01

Last updated

2019-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Legal Medical Skin Wounds

Brief summary

Identify the cytokine or combination of cytokines, with the best diagnostic performance to characterize the vital nature of a skin wound in the body.

Detailed description

Determining the vitality of skin wounds, that is to say their antemortem character, is an important issue in forensic pathology. The only criterion vitality currently recognized (but whose diagnostic performance remains limited) is the microscopic demonstration of an inflammatory infiltrate of neutrophils. The search for more reliable diagnostic biomarkers is required. By their early expression of the injury site, inflammatory cytokines are potential candidates and their quantification in injured skin could optimize the diagnosis of vitality injury. The objective is to identify the cytokine or combination of cytokines, with the best diagnostic performance to characterize the vital nature of a skin wound in the body.

Interventions

OTHERautopsy

At autopsy achieving adequate sampling of lesions and healthy skin

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Adult died 18 years or more * Having at least one recent ante-mortem skin wound (occurring less than 4 hours prior to death) * Hours of death and the establishment of the ante-mortem wound known (date, hours and minutes)

Exclusion criteria

* Immunocompromised patients (HIV infection, immunosuppressive therapy ...) * Putrefaction signs (abdominal patch of green ...)

Design outcomes

Primary

Measure	Time frame	Description
measures cytokines	1 day	multiplex analysis electrochemoluminescence: Six cytokines candidates selected from a literature review (IFN-γ, IL-1β, IL-6, IL-10, IL-12 p70, TNF-α) will be assayed in conjunction with the MSD technology (V-PLEX proinflammatory Panel 1 human Kit) after tissue extraction and determination of total protein concentration in each sample.

Countries

France

Contacts

Primary ContactPierre-Antoine PEYRON, MD

pa-peyron@chu-montpellier.fr467338586

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026